Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2008;102:415-422
Published online before print December 13, 2007, doi: 10.1161/CIRCRESAHA.107.157859
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
102/4/415    most recent
CIRCRESAHA.107.157859v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Montano, M. M.
Right arrow Articles by Watanabe, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Montano, M. M.
Right arrow Articles by Watanabe, M.
Related Collections
Right arrow Cardiac development
Right arrowRelated Article
(Circulation Research. 2008;102:415.)
© 2008 American Heart Association, Inc.


Molecular Medicine

Mutation of the HEXIM1 Gene Results in Defects During Heart and Vascular Development Partly Through Downregulation of Vascular Endothelial Growth Factor

Monica M. Montano, Yong Qui Doughman, Huayun Deng, Laura Chaplin, Jianqi Yang, Nancy Wang, Qiang Zhou, Nicole L. Ward, Michiko Watanabe

From the Departments of Pharmacology (M.M.M., H.D., L.C.), Biochemistry (J.Y.), and Dermatology (N.L.W.), Case Western Reserve University, Cleveland, Ohio; Division of Pediatric Cardiology (Y.Q.D., M.W.), Department of Pediatrics, Rainbow Babies and Children’s Hospital, and Department of Pathology (N.W.), University Hospitals of Cleveland, Ohio; and Department of Molecular and Cell Biology (Q.Z.), University of California, Berkeley.

Correspondence to Dr Monica M. Montano, Case Western Reserve University School of Medicine, Department of Pharmacology, H.G. Wood Bldg W307, 2109 Adelbert Rd, Cleveland, OH 44106. E-mail mxm126{at}case.edu

Our previous studies and those of others indicated that the transcription factor Hexamethylene-bis-acetamide-inducible protein 1 (HEXIM1) is a tumor suppressor and cyclin-dependent kinase inhibitor, and that these HEXIM1 functions are mainly dependent on its C-terminal region. We provide evidence here that the HEXIM1 C-terminal region is critical for cardiovascular development. HEXIM1 protein was detected in the heart during critical time periods in cardiac growth and chamber maturation. We created mice carrying an insertional mutation in the HEXIM1 gene that disrupted its C-terminal region and found that this resulted in prenatal lethality. Heart defects in HEXIM11 to 312 mice included abnormal coronary patterning and thin ventricular walls. The thin myocardium can be partly attributed to increased apoptosis. Platelet endothelial cell adhesion molecular precursor-1 staining of HEXIM11 to 312 heart sections revealed decreased vascularization of the myocardium despite the presence of coronary vasculature in the epicardium. The expression of vascular endothelial growth factor (VEGF), known to affect angioblast invasion and myocardial proliferation and survival, was decreased in HEXIM11 to 312 mice compared with control littermates. We also observed decreased fibroblast growth factor 9 (FGF9) expression, suggesting that effects of HEXIM1 in the myocardium are partly mediated through epicardial FGF9 signaling. Together our results suggest that HEXIM1 plays critical roles in coronary vessel development and myocardial growth. The basis for this role of HEXIM1 is that VEGF is a direct transcriptional target of HEXIM1, and involves attenuation a repressive effects of C/EBP{alpha} on VEGF gene transcription.


Key Words: HEXIM1 • heart • vascular • development


Related Article:

Vascular Endothelial Growth Factor Gene Regulation by HEXIM1 in Heart
Atsushi Asakura
Circ. Res. 2008 102: 398-400. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
Mol. Endocrinol.Home page
N. Shimizu, N. Yoshikawa, T. Wada, H. Handa, M. Sano, K. Fukuda, M. Suematsu, T. Sawai, C. Morimoto, and H. Tanaka
Tissue- and Context-Dependent Modulation of Hormonal Sensitivity of Glucocorticoid-Responsive Genes by Hexamethylene Bisacetamide-Inducible Protein 1
Mol. Endocrinol., December 1, 2008; 22(12): 2609 - 2623.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Ogba, L. J. Chaplin, Y. Q. Doughman, K. Fujinaga, and M. M. Montano
HEXIM1 Regulates 17{beta}-Estradiol/Estrogen Receptor-{alpha}-Mediated Expression of Cyclin D1 in Mammary Cells via Modulation of P-TEFb
Cancer Res., September 1, 2008; 68(17): 7015 - 7024.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
A. Asakura
Vascular Endothelial Growth Factor Gene Regulation by HEXIM1 in Heart
Circ. Res., February 29, 2008; 102(4): 398 - 400.
[Full Text] [PDF]